• Lipid Peroxidation (MDA) Assay Kit: Advanced Use Cases & Wor

  2026-04-30

  The Lipid Peroxidation (MDA) Assay Kit empowers researchers to quantify malondialdehyde with unmatched accuracy using both colorimetric and fluorescence readouts. This article delivers evidence-backed protocol optimizations, experimental troubleshooting guidance, and translational insights for leveraging the kit in oxidative stress and ferroptosis studies.

• Danazol (Danocrine) in Endocrine Bench Research: Applied Pro

  2026-04-30

  Danazol (Danocrine) is a pivotal tool for probing androgen receptor signaling, inhibition of steroidogenesis, and disease modeling in both endocrine and oncology domains. This article delivers a comprehensive, evidence-driven guide to experimental workflows, troubleshooting, and innovative applications, leveraging APExBIO's high-purity Danazol for reproducible, high-impact results.

• VX-661: Evidence-Based Guide to F508del CFTR Correction

  2026-04-29

  VX-661 (F508del CFTR corrector) is a validated small molecule that restores trafficking and function of the mutant CFTR protein in cystic fibrosis research. Its mechanism, efficacy, and protocol parameters are supported by peer-reviewed data and product specifications, making it a foundational tool for investigating CFTR modulation strategies.

• Captopril in Neurovascular and Gastrointestinal Research: Be

  2026-04-29

  Explore how Captopril, a potent ACE inhibitor, advances neurovascular and gut motility research through precise bradykinin pathway modulation. This in-depth analysis delivers new insights distinct from standard hypertension or oncology workflows.

• Phenothiazines Boost Macrophage Antibacterial Activity via A

  2026-04-28

  This study demonstrates that phenothiazines, including dopamine D2 receptor inhibitors, enhance macrophage antibacterial function by inducing both autophagy and reactive oxygen species (ROS) accumulation. These findings support host-directed strategies against intracellular bacterial infections, offering new directions for overcoming antibiotic resistance.

• GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor for Redox

  2026-04-28

  GKT137831 empowers researchers to dissect oxidative stress pathways with nanomolar precision, offering robust inhibition of Nox1 and Nox4-driven reactive oxygen species. Its versatility spans from vascular remodeling and fibrosis models to advanced redox signaling studies, with built-in protocol flexibility for reproducible and high-sensitivity results.

• Dovitinib (TKI-258, CHIR-258): Reliable RTK Inhibition for C

  2026-04-27

  This article explores real-world laboratory challenges in cell viability and apoptosis assays, demonstrating how Dovitinib (TKI-258, CHIR-258) (SKU A2168) from APExBIO addresses critical issues of reproducibility, potency, and workflow efficiency. Evidence-backed scenario Q&As guide researchers in deploying this multitargeted RTK inhibitor for robust, data-driven results.

• USP36-Snail1 Axis Promotes Ribosome Biogenesis Under Ribotox

  2026-04-27

  This study uncovers how USP36-driven stabilization of nucleolar Snail1 enhances ribosome biogenesis and cancer cell survival during ribotoxic stress. These findings provide mechanistic insight into solid tumor resistance to ribosome-targeting therapies and suggest new intervention strategies targeting the JNK-USP36-Snail1 pathway.

• Calnexin Modulation Shapes CFTR Variant Rescue by Correctors

  2026-04-26

  Tedman et al. systematically dissect how the ER chaperone calnexin influences the expression and pharmacological correction of over 200 CFTR variants, revealing domain-specific requirements for effective rescue. These insights provide a mechanistic foundation for refining cystic fibrosis therapeutic strategies and optimizing small-molecule corrector use.

• Tolazoline as an α2-Adrenergic Receptor Antagonist: Applied

  2026-04-25

  Tolazoline’s dual mechanism—α2-adrenergic receptor antagonism and ATP-sensitive potassium channel blockade—makes it a versatile tool for dissecting neuroendocrine and airway smooth muscle pathways. This guide details practical workflows, nuanced troubleshooting, and data-backed protocol enhancements for maximizing Tolazoline’s impact in translational pharmacological research.

• Molidustat (BAY85-3934): Redefining HIF Stabilization in Ren

  2026-04-24

  This thought-leadership article explores the mechanistic rationale and translational promise of Molidustat (BAY85-3934), a HIF prolyl hydroxylase inhibitor, in renal anemia therapy. By integrating recent apoptosis research and real-world experimental insights, it provides strategic guidance for researchers pursuing innovative treatments for chronic kidney disease anemia.

• Optimizing mRNA Loading in Kidney-Targeted Nanoparticles

  2026-04-24

  This study investigates how the incorporation of various excipients can enhance the mRNA payload capacity of polymeric mesoscale nanoparticles designed for kidney-targeted delivery. The findings reveal that strategic excipient selection not only boosts mRNA encapsulation efficiency but also preserves nanoparticle size and biocompatibility, offering new directions for renal gene therapy research.

• Palonosetron Hydrochloride in Preventing Chemotherapy-Induce

  2026-04-23

  This article reviews the innovation and clinical impact of palonosetron hydrochloride as a 5-HT3 receptor antagonist for preventing chemotherapy-induced nausea and vomiting (CINV). The study demonstrates palonosetron’s superior efficacy in controlling both acute and delayed emesis compared to earlier antiemetics, with implications for improving patient tolerance of intensive chemotherapy regimens.

• Pepstatin A: Benchmark Aspartic Protease Inhibitor Profiles

  2026-04-23

  Pepstatin A is a well-characterized aspartic protease inhibitor with submicromolar to micromolar potency against key enzymes such as pepsin, cathepsin D, renin, and HIV protease. Its specificity and solubility profile make it a reliable standard for viral protein processing and osteoclast differentiation inhibition studies. APExBIO provides high-purity Pepstatin A (SKU A2571) optimized for reproducible biomedical workflows.

• H 89 2HCl: Selective PKA Inhibition and cAMP Pathway Dissect

  2026-04-22

  H 89 2HCl, also known as N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide, is a highly selective inhibitor of protein kinase A (PKA) with nanomolar potency. It enables precise modulation of cAMP/PKA signaling in cellular research and is validated for dissecting mechanisms such as forskolin-induced neurite outgrowth inhibition and protein phosphorylation. Its selectivity profile, solubility properties, and best-practice use parameters make it a leading tool for biochemical studies.

16611 records 1/1108 page Next 12345 下5页 Last page